ALPHARETTA, Ga., Jan. 11, 2016 /PRNewswire/ -- ViveBio, a leader in biological specimen stabilization technologies, announced today the results of a study presented at the HEP DART conference held in Wailea, Hawaii. The study, which was conducted by ZeptoMetrix, combined their SeroDetect quality control panels with the ViveST matrix technology to produce dried, shelf stable quality controls, which could be rehydrated on demand and tested in a commercially available, FDA cleared immunodiagnostic system.
“The results of this preliminary study support our strategy to introduce a technology platform that allows IVD manufacturers and suppliers to eliminate cold chain logistics for control and calibration material,” said Timothy W. Murray, president of ViveBio. “The company has previously demonstrated the utility of the ViveST technology with molecular diagnostic controls, including dried, shelf stable run controls for CLIA-waived Point of Care systems. This study now extends our work in the field to include serological controls and calibration sets, which represents a significant market opportunity worldwide. In 2016 we plan to launch our new single use, shelf stable, control delivery device that is compatible with both molecular and non-molecular material.”
End users and manufacturers in developed healthcare markets benefit from the elimination of cold chain logistics and refrigerated storage upon delivery. Governments and health systems in resource limited healthcare markets are faced with the challenge of implementing diagnostic quality assurance schemes were cold chain logistics are sparse or non existent. “We’re very excited about the results of this preliminary study which show the ViveST technology can be combined with ZeptoMetrix serological controls to create a solution for laboratories throughout the world,” added Michael Hershfield, vice president, sales and marketing for ZeptoMetrix. “Providing customers with a dried, shelf-stable quality control panel can free them from costly cold chain logistics and expand the reach of diagnostic testing.”
Summary of study available here: http://www.vivebio.com/media/posters/2015-12-06-hepdart-serological-controls.pdf
About Vive Bio, LLC.
ViveBio, LLC is a biotechnology company focused on providing high quality yet cost-effective solutions for specimen transportation, storage and blood component separation, along with cutting edge clinical diagnostics. The company’s manufacturing and corporate office are located in Alpharetta, Georgia. For more information regarding ViveST and recent scientific publications, please visit the ViveBio website at www.vivebio.com. Company Contact: Brad Nelson, Investor Relations: nelson@vivebio.com or 877-814-7004.
About ZeptoMetrix Corporation
ZeptoMetrix Corporation (ZMC) is an industry leader and innovator identified with quality, reliable and trusted products, services and solutions for Infectious Disease Diagnostic Development. ZeptoMetrix offerings support all phases of Infectious Disease Research, Design & Development; Proficiency, Validation & Verification; Quality Control; Testing Services; Manufacturing; BioStorage; Regulatory Submissions and Test Kit Commercialization. For additional information regarding ZeptoMetrix and its extensive range of controls and calibrators for serological assays and Nucleic Acid Testing, please visit the ZeptoMetrix website at www.zeptometrix.com or contact: Michael Hershfield, VP Sales and Marketing: mhershfield@zeptometrix.com or 508-553-5852.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/combined-technologies-of-vivebio-and-zeptometrix-featured-in-study-presented-at-hep-dart-2015-300202200.html
SOURCE ViveBio, LLC
